Nantahala Capital Management, LLC Uni Qure N.V. Transaction History

Nantahala Capital Management, LLC

$1.55 Billion
Q1 2024

A detailed history of Nantahala Capital Management, LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Nantahala Capital Management, LLC holds 3,088,082 shares of QURE stock, worth $13.8 Million. This represents 1.03% of its overall portfolio holdings.

Number of Shares

3,088,082

Previous 2,958,027 4.4%

Holding current value

$13.8 Million

Previous $20 Million 19.81%

% of portfolio

1.03%

Previous 1.35%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.82 - $6.93 $626,865 - $901,281	130,055 Added 4.4%	3,088,082 $16.1 Million
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $370,296 - $543,934	-65,772 Reduced 2.18%	2,958,027 $20 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $1.17 Million - $2.07 Million	174,815 Added 6.14%	3,023,799 $20.3 Million
Q2 2023 Aug 14, 2023	SELL	$11.12 - $22.2 $2.46 Million - $4.91 Million	-221,377 Reduced 7.21%	2,848,984 $32.6 Million
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $6.92 Million - $8.54 Million	370,122 Added 13.71%	3,070,361 $61.8 Million

Q4 2022 Feb 14, 2023	SELL	$18.12 - $27.32 $3.65 Million - $5.51 Million	-201,690 Reduced 6.95%	2,700,239 $61.2 Million
Q3 2022 Nov 10, 2022	SELL	$16.98 - $25.54 $3.21 Million - $4.82 Million	-188,828 Reduced 6.11%	2,901,929 $54.4 Million
Q2 2022 Aug 15, 2022	BUY	$13.15 - $20.45 $3.67 Million - $5.71 Million	279,298 Added 9.93%	3,090,757 $57.6 Million
Q1 2022 May 13, 2022	BUY	$14.54 - $21.5 $6.52 Million - $9.64 Million	448,146 Added 18.96%	2,811,459 $50.8 Million
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $12.2 Million - $21.8 Million	604,095 Added 34.34%	2,363,313 $49 Million
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $92,283 - $135,604	-3,548 Reduced 0.2%	1,759,218 $56.3 Million
Q2 2021 Aug 16, 2021	BUY	$29.97 - $37.17 $2.69 Million - $3.34 Million	89,875 Added 5.37%	1,762,766 $54.3 Million
Q1 2021 May 14, 2021	BUY	$29.24 - $42.03 $1.06 Million - $1.53 Million	36,352 Added 2.22%	1,672,891 $56.4 Million
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $1.88 Million - $2.69 Million	53,181 Added 3.36%	1,636,539 $59.1 Million
Q3 2020 Nov 16, 2020	BUY	$35.98 - $47.66 $547,219 - $724,860	15,209 Added 0.97%	1,583,358 $58.3 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $6.36 Million - $9.56 Million	-141,123 Reduced 8.26%	1,568,149 $70.7 Million
Q1 2020 May 14, 2020	BUY	$40.01 - $73.97 $15.1 Million - $27.9 Million	377,434 Added 28.34%	1,709,272 $81.1 Million
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $23.7 Million - $47.5 Million	-637,000 Reduced 32.35%	1,331,838 $95.4 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $20.7 Million - $40.4 Million	526,378 Added 36.49%	1,968,838 $77.5 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $4.02 Million - $6.27 Million	-76,230 Reduced 5.02%	1,442,460 $113 Million
Q1 2019 May 15, 2019	SELL	$27.39 - $68.41 $26.3 Million - $65.7 Million	-959,977 Reduced 38.73%	1,518,690 $90.6 Million
Q4 2018 Feb 14, 2019	BUY	$22.8 - $33.93 $13.6 Million - $20.2 Million	596,196 Added 31.67%	2,478,667 $71.4 Million
Q3 2018 Nov 14, 2018	BUY	$29.75 - $43.08 $3.75 Million - $5.43 Million	126,032 Added 7.18%	1,882,471 $68.5 Million
Q2 2018 Aug 14, 2018	SELL	$21.96 - $39.94 $1.83 Million - $3.33 Million	-83,335 Reduced 4.53%	1,756,439 $66.4 Million
Q1 2018 May 15, 2018	SELL	$17.1 - $26.61 $703,083 - $1.09 Million	-41,116 Reduced 2.19%	1,839,774 $43.2 Million
Q4 2017 Feb 14, 2018	BUY	$9.47 - $19.59 $7.21 Million - $14.9 Million	761,007 Added 67.95%	1,880,890 $36.8 Million
Q3 2017 Nov 14, 2017	BUY	$7.7 - $9.6 $8.62 Million - $10.8 Million	1,119,883	1,119,883 $10.8 Million

Others Institutions Holding QURE

# of Institutions

149

Shares Held

34.1M

Call Options Held

1.07M

Put Options Held

603K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $208M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.

Account

Nantahala Capital Management, LLC Uni Qure N.V. Transaction History